Fusion Pharmaceuticals Inc.
Fusion Pharmaceuticals Inc. (FUSN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
fusn · pe ratio · data through Dec 31, 2023
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Fusion Pharmaceuticals Inc. (FUSN) measures how much investors pay for each dollar of the company's trailing earnings. FUSN's current PE ratio of N/A is calculated by dividing its stock price of $21.55 by its TTM earnings per share of -$1.45.
Source: FMP · /ratios-ttm · /analyst-estimates · 2023-12-31
PE Ratio History
2017 – 2023 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Fusion Pharmaceuticals Inc.You FUSN | $1.8B | N/A | — | -$1.45 |
 Ambrx Biopharma Inc. AMAM | $1.8B | N/A | — | -$2.02 |
 Astrana Health, Inc. ASTH | $1.9B | 54.15x | — | $0.46 |
 BELLUS Health Inc. BLU | $1.9B | N/A | — | -$0.66 |
 Calliditas Therapeutics AB (publ) CALT | $2.1B | N/A | — | -$17.37 |
 CinCor Pharma, Inc. CINC | $1.3B | N/A | — | -$1.42 |
 CTI BioPharma Corp. CTIC | $1.2B | N/A | — | -$0.79 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2023-12-31Latest FY2023 | — | $-1.45 | — | |
2022-12-31 FY2022 | — | $-2.00 | — | |
2021-12-31 FY2021 | — | $-1.90 | — | |
2020-12-31 FY2020 | — | $-3.56 | — | |
2019-12-31 FY2019 | — | $-0.10 | — | |
2018-12-31 FY2018 | — | $-0.62 | — | |
2017-12-31 FY2017 | — | $-0.34 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Fusion Pharmaceuticals Inc. (FUSN) measures how much investors pay for each dollar of the company's trailing earnings. FUSN's current PE ratio of N/A is calculated by dividing its stock price of $21.55 by its TTM earnings per share of -$1.45.
Frequently asked questions
FUSN pe ratio · 6 questionsFUSN's current PE ratio is N/A as of 2026-06-09, based on a stock price of $21.55 and TTM EPS of -$1.45. Data sourced from Financial Modeling Prep via FUSN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Fusion Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09